Quantitative MRI Imaging in Diffuse Liver Diseases
NCT04626492 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2021-02-21
Summary
As we all know, the early diagnosis and accurate staging of liver fibrosis are very important to reduce the incidence of liver cirrhosis and liver cancer. And the accurate evaluation of hepatic fibrosis is of great significance to the prediction of residual liver function after liver surgery. Therefore, clinicians pay more and more attention to the qualitative and quantitative diagnosis of hepatic fibrosis, liver cirrhosis and hepatic steatosis involved in diffuse liver diseases(such as fatty liver, viral hepatitis, autoimmune hepatitis ). And now, liver biopsy is commonly used as the gold standard for the evaluation of steatohepatitis and fibrosis. However, this test is invasive, has low patient acceptance. So more and more clinicians recommend non-invasive methods to qualitatively and quantitatively evaluate the liver steatosis, fibrosis and cirrhosis in diffuse liver diseases. At present, serum markers, ultrasonic elastography and magnetic resonance imaging have good accuracy in the non-invasive detection and evaluation of liver cirrhosis. However, serum markers are not liver-specific, and a single serum marker is not enough to accurately reflect the degree of liver fibrosis. Furthermore, whether the non-invasive liver fiber diagnostic model is suitable for patients with liver disease in China remains to be further verified. At present, transient elastography has been recommended for the non-invasive staging of hepatic fibrosis by the clinical practice guidelines of the European Association for liver Research and the Asia-Pacific Association for liver Research. But as serum markers, it still has low sensitivity and specificity in the diagnosis of early hepatic fibrosis, and is highly operationally dependent. With the development of MRI technology, some MRI quantitative techniques, such as T1mapping, T2mapping,Intravoxel incoherent motion diffusion-weighted magnetic resonance imaging(IVIM-DWI), dynamic contrast enhanced magnetic resonance imaging(DCE-MRI) can be used to qualitatively and quantitatively diagnosis of liver fat, hepatic fibrosis and cirrhosis. And iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence(IDEALIQ) usually used to evaluate liver fat. The existing research results showed that MRI quantitative techniques has a high value in quantitative diagnosis of advanced hepatic fibrosis and cirrhosis. But it still has some limitations in quantitative diagnosis of early liver fibrosis. And what's more,some of the research results still can not reach a consensus. Therefore, based on the multi-parameter potential of MRI and the characteristics of metabolic evaluation. This study will adjust some of the parameters of MRI quantitative techniques, and through large sample datas, combined with a variety of quantitative techniques to explore the application value of MRI quantitative techniques in the quantitative diagnosis of liver diffuse lesions, especially in the early stage of liver fibrosis.
Conditions
- Fibrosis and Cirrhosis of Liver
Interventions
- DIAGNOSTIC_TEST
-
Quantitative MRI imaging
Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
Sponsors & Collaborators
-
Fifth Affiliated Hospital, Sun Yat-Sen University
lead OTHER
Principal Investigators
-
Shaolin Li, Director · Radiology Department,the Fifth Affiliated Hospital of Sun Yat-sen University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-08-01
- Primary Completion
- 2022-07-31
- Completion
- 2022-12-31
Countries
- China
Study Locations
More Related Trials
-
Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study
NCT02958592 ·Status: COMPLETED
-
Magnetic Resonance Imaging in the Evaluation of Liver Fibrosis
NCT01572064 ·Status: COMPLETED ·Phase: NA
-
Radiomics for Diagnosing Liver Diseases and Evaluating Progression
NCT03221049 ·Status: UNKNOWN
-
Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging
NCT02480972 ·Status: COMPLETED ·Phase: NA
-
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
NCT05384652 ·Status: ACTIVE_NOT_RECRUITING
-
Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis
NCT02682108 ·Status: COMPLETED ·Phase: NA
-
Development of Non-Invasive MRI Applications for Liver Fibrosis and Inflammation
NCT05168982 ·Status: COMPLETED
-
Usefulness of Multi-parametric, Quantitative MR Imaging for Staging of Hepatic Fibrosis in the Patients With Chronic Hepatitis
NCT01981421 ·Status: UNKNOWN
-
Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study
NCT02143180 ·Status: UNKNOWN
-
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions
NCT07055048 ·Status: NOT_YET_RECRUITING
-
68Ga-FAPI PET/CT in Liver Fibrosis Patients
NCT04533828 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Identification of Hepatic Fibrosis Using 4D-MRI
NCT05385237 ·Status: RECRUITING ·Phase: NA
-
18F-FAPI PET in the Diagnosis of Liver Fibrosis
NCT05262647 ·Status: UNKNOWN
-
NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis
NCT05734599 ·Status: UNKNOWN
-
Liver and Spleen Stiffness Measured by 2D-SWE for Diagnosis of Liver Fibrosis in Patients With cACLD
NCT06147934 ·Status: RECRUITING
-
Evaluation of Hepatic Fibrosis on Multiparametric MRI
NCT03085342 ·Status: UNKNOWN ·Phase: NA
-
Comparison of Multiphase and Monophasic Arterial Hepatic MRI in the Detection of Arterial Enhancement of CHC Nodules
NCT04687280 ·Status: COMPLETED
-
Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma
NCT00842647 ·Status: UNKNOWN
-
Methods to Detect Liver Fibrosis
NCT03027700 ·Status: TERMINATED ·Phase: NA
-
Assessment of Liver Fibrosis and Prognosis in Chinese Patients With CHB Infection Using STE/STQ Elastography
NCT03530657 ·Status: UNKNOWN
-
Exploratory Study of MRI Biomarkers of NASH
NCT06626074 ·Status: RECRUITING ·Phase: NA
-
Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications
NCT02936856 ·Status: UNKNOWN ·Phase: NA
-
Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis
NCT03842748 ·Status: UNKNOWN
-
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique
NCT00172705 ·Status: UNKNOWN
-
Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis
NCT06663904 ·Status: COMPLETED